LipidBrick® is a novel range of proprietary cationic lipids dedicated to the formulation of LNPs for the development of mRNA-based vaccines and thera...
Meet Polyplus at booth #131 during the 15th Annual PEGS Europe Protein & Antibody Engineering Summit in Lisbon, Portugal on 14th - 16th November 2023. Dont miss the opportunity to hear our talk by our expert Marine Houdou on Modular DNA Assembly to Recombinant Protein Production at Polyplus and our poster presentations on how to improve protein production yields in mammalian cells through plasmid engineering and transfection optimisation.
Marine Houdou – Plasmid Engineering Specialits
Talk : Modular DNA Assembly to Recombinant Protein Production at Polyplus | Wednesday 15 November – 09:45 – 10:00 AM
Talk Summary : With recent acquisitions of e-Zyvec and Xpress Biologics, Polyplus offers now a unique integrated pDNA service with plasmid engineering and manufacturing. Our unique DNA assembly technology and proprietary software allow the tailor-made design and production of any plasmid. Synergistically, the 30+ years of combined expertise at Xpress Biologics reinforces our services at Polyplus to support recombinant protein manufacturing from 100 mg to 50 g at Research, GLP and GMP grade.
Improving protein production for vaccine development with FectoPRO® A case study with Eppendorf SciVario® twin Bioprocess Controller
Bioreactor transfection is a method of deliberately introducing plasmids into large numbers of cultured cells for protein production The global COVID 19 health crisis caused by the severe acute respiratory syndrome coronavirus 2 (SARS CoV 2 demonstrated the imperativity to produce large quantities of vaccine components such as spike proteins, the predominant antigen of SARS CoV 2 S vaccines. To demonstrate feasibility, production of the SARS CoV 2 S HexaPro spike protein was conducted using the suspension adapted HEK 293 cell platform Expi 293 F ™transfected with spike protein encoding plasmid DNA to achieve high yield, the transfection was performed using FectoPRO ® in a BioBLU ® 1 c Single Use Bioreactor controlled by the SciVario ® twin bioreactor control system.
Improving mAbs yield and quality through plasmid engineering
Recombinant monoclonal antibodies (rmAbs) will become part of the therapeutical arsenal for numerous pathologies, The generalization of their usage will be driven by faster development program and lower production costs, both criteria being directly dependent on the productivity of our bioprocesses. During the past decades impressive progresses have been made regarding the bioproduction equipment’s, cell models and purification processes. The improvement of the biomolecular components, that are the plasmids, has somewhat lagged behind such developments. With the booming of molecular technologies of DNA assembly methods, including the proprietary e-Zyvec® method from Polyplus®, we have new opportunities to explore the potential of plasmid engineering as another leverage to increase yield and quality of rmAbs bioproduction.
Discover Our Applications
Cell & Gene Therapy
Success of Gene and Cell Therapies is dependent on efficient production of viral vectors that require optimized transfection reagents and viral vector engineering
RNA/DNA in vivo delivery is the most powerful alternative to viral vectors for nucleic acid-based therapies. They offer substantial advantages in terms of reliability,safety and costs for nucleic-acid based therapies
Broad range of solutions is needed for manufacturing of functional proteins or antibodies at the desired scale in bacteria, yeast and mammalian cell expression systems
Optimised plasmid engineering and specific transfection reagents are key to enable protein expression in a wide range of adherent and suspension mammalian cell types